| || |
Concrete, innovative solutions
|Laboratoire Sogeval S.A. is created following the merger of Thespos, a subsidiary of the Sanders group, and Sepval, the veterinary division of the |
Pierre Fabre group.
The restructuring of the Laval production unit provides the laboratory with a site compliant with European pharmaceutical standards and ideally suited to best production practices.
Sogeval becomes the Animal Health subsidiary of the Glon group.
Sogeval acquires a second production site in Louverné, France. This investment enables the company to specialise its manufacturing sites.
The Research and Development Department opens offices in the Laval Technopole, in regulatory technical facilities covering 750 sq. meters.
Sogeval becomes a member of the Genevet network.
Sogeval creates its first subsidiary in the United States.
The Companion Animal Division:
|From 1978 to 2005, the Sogeval Companion Animal Division markets products under the SEPVAL brand|
Sepval is the first French laboratory to market drugs specifically
developed for cats.
Sepval demonstrates its creative talents concerning tablets with the launch of Pet-Phos, a vitaminised mineral supplement for dogs.
European patent application for canine Delicament.
Worldwide patent application for feline Delicament.
The PET-PHOS range becomes the leader in the French market for vitaminised mineral supplements for dogs and cats.
Launch of the dermatology range and the first Nutraceuticals (Actis)
Launch of the first two feline Delicaments: Amoxival and Sépante
Launch of the dentistry range
Sepval, partner of veterinary practitioners, offers veterinarians preferred access to conferences and practical work in dermatology, surgery and dentistry throughout France. This programme is part of the Sepval regional expansion policy. These practical professional workshops are held every two years.
Launch of Théma, a Sepval publication designed to provide veterinary practitioners with additional technical information concerning the latest developments in therapeutics.
The SEPVAL brand is changed to match the company name: SOGEVAL. Launch of the Délicaments range abroad.
Sogeval Pets becomes the leader in oral antibiotic therapy for dogs and cats in the French market. Launch of the new dermatology range Douxo, based on phytosphingosine, an exclusive molecule, in both the American and Japanese markets.
Sogeval pursues its growth in dermatology with the launch of the Douxo Calm line, and in dentistry with the launch of Prozym Proden Plaque Off.
Sogeval returns to the equine market with the launch of Domidine, a sedative and analgesic based on detomidine.
The Livestock Division:
|Since the early 1980s, Sogeval is known for its slogan "Hygiene in Action".|
In 1987, a novel formula is invented in the Research and Development Department, resulting in the creation of the disinfectant TH4+ (in liquid form). Rapidly patented, this new disinfectant becomes the forerunner of a new generation.
TH4+ becomes the French leader in the market for disinfectants for breeding plant and equipment.
Sogeval proposes an alternative to the use of drug premixes by launching the range of soluble oral powders and oral solutions of antibiotics:
1997 : Doxyval 20 and Amoxival 10
1999 : Doxyval 5
2001 : Amoxival 20
Mefisto, disinfectant and insecticide (liquid format), patented worldwide, the sibling of TH4+, revolutionises the practice of hygiene in breeding.
Launch of Virofree, a disinfectant powder recognised for its virucidal properties.
Sogeval expands its offer in the historical drug premixes range with the launch of new products :
2000 : Sultrival, Doxyval 20 and Doxyval 40
2001 Amoxival 20
2002 : Amoxival 40
Backed by its experience in prevention, Sogeval enters the new preventive domain by developing a new generation of nutritional supplements: Nutraceuticals. A new approach perfectly suited to the latest preventive trends in breeding.
Launch of Pracetam, the first European paracetamol for animal care.
Launch of Perlium, a new generation of drug premixes.
Two years after its launch in France, Pracetam obtains a drug license in 21 new European countries.
Launch of TH5, a new breeding disinfectant approved as a bactericide, antifungal, and virucide, effective against the bird flu virus: the H5N1 strain